Figure 3. Non–Small-Cell Lung-Cancer (NSCLC) Incidence, Incidence-Based Mortality, and Survival Trends among Men and Women.

Panel A shows age-adjusted incidence (blue) and incidence-based mortality (red) for the NSCLC histologic subtype among men and women. Incidence was adjusted for reporting delays. The line segments of each curve were selected with the Joinpoint program, and the percentage associated with each line represents the annual percentage change during the indicated range of years. Asterisks indicate annual percentage changes that are significantly different from zero (P<0.05). The dashed vertical line indicates calendar year 2013, when epidermal growth factor receptor (EGFR)–directed first-line therapy was approved by the Food and Drug Administration (FDA). For each incidence-based mortality curve, an arrow indicates the point at which there is a change in slope for mortality corresponding with the timing of routine testing for molecular alterations in EGFR and FDA approval for targeted therapy. Panel B shows 2-year lung-cancer–specific survival according to year of NSCLC diagnosis among men and women. Results are shown for the SEER 18-registry database. The following International Classification of Diseases for Oncology, 3rd Edition (ICD-O-3), histology codes were used to define the NSCLC subtype — squamous and transitional cell: 8051, 8052, 8070–8076, 8078, 8083, 8084, 8090, 8094, 8120, and 8123; adenocarcinoma: 8015, 8050, 8140, 8141, 8143–8145, 8147, 8190, 8201, 8211, 8250–8255, 8260, 8290, 8310, 8320, 8323, 8333, 8401, 8440, 8470, 8471, 8480, 8481, 8490, 8503, 8507, 8550, 8570–8572, 8574, and 8576; large cell: 8012–8014, 8021, 8034, and 8082; non–small-cell carcinoma, not otherwise specified: 8046; and other specified carcinomas: 8003, 8004, 8022, 8030, 8031–8033, 8035, 8200, 8240, 8241, 8243–8246, 8249, 8430, 8525, 8560, 8562, and 8575.